Galectin Therapeutics Inc. (GALT) Dividend History

Galectin Therapeutics Inc. (GALT) is a biotechnology company focused on developing therapies that target galectin proteins, which play a role in fibrosis, inflammation, and cancer. Their primary pathways involve developing drugs to treat various fibrotic and immune-related conditions, including non-alcoholic steatohepatitis (NASH) and other liver diseases. The company leverages its expertise in galectin biology to advance novel therapeutics aimed at addressing unmet medical needs.

4960 Peachtree Industrial Boulevard, Norcross, GA, 30071
Phone: 678-620-3186

Dividend History

Galectin Therapeutics Inc. currently does not pay dividends

Company News

Galectin Therapeutics to Present at the 2025 MASH-TAG Conference

Galectin Therapeutics announced that the top-line results of the NAVIGATE trial in patients with MASH cirrhosis and portal hypertension will be presented at the 2025 MASH-TAG Conference. The company's executive leadership will also host one-on-one meetings during the JP Morgan Healthcare Conference to discuss the NAVIGATE topline results and the next steps for the belapectin program.

GlobeNewswire Inc.
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update

Galectin Therapeutics reported financial results for Q2 2024, with a net loss of $12.4 million. The company's lead drug, belapectin, is in a Phase 2b/3 trial for the treatment of MASH-related liver cirrhosis, with interim data expected in December 2024.

GlobeNewswire Inc.
Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 Congress

NORCROSS, Ga., June 04, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3, today announced that it will attend the EASL 2024 meeting and deliver a scientific presentation. The meeting will be held June 5-8, 2024, in Milan, Italy.

GlobeNewswire Inc.
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update

NORCROSS, Ga., May 15, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the quarter ended March 31, 2024.

GlobeNewswire Inc.
Wall Street Breakfast: The Week Ahead

Geopolitical tensions in the Middle East, earnings reports from major companies, and the upcoming bitcoin halving event are set to drive market focus this...

Seeking Alpha

Featured Companies: ABT ALAB ALLY AUNA AXP BAC BLZE BMR BNTC BX CPRI CSX GDTC GL GP GS IDCC ISRG IZM JNJ KMI LVS MS MTB NFLX PERI PG RDDT RIVN SBGI SCHW SIRI TPR TRV UAL UNH USB VFS VZ WBUY

Dividend data last updated 06/07/2025 20:35:34 UTC